Captixbio is delighted to welcome Professor Martina Stenzel to its Scientific & Clinical Advisory Panel.
With a career spanning over 20 years focusing on polymer science and in-depth analysis to understand material properties, Martina’s work has culminated with her being named Fellow of the Australian Academy of Science, Fellow of the Royal Society of New South Wales and ARC Laureate Fellow.
Martina’s interest and expertise is in the design of new polymeric materials for biomedical applications, in particular for drug delivery and the preparation of new polymer scaffolds to optimise the interaction between cells and the materials.
“If a polymer material is very suitable for applications such as tissue engineering or drug delivery depends very much on our understanding of the polymers on the molecular level,” said Professor Stenzel. “To truly succeed in this field, we need to understand the behaviour of the material on the nanoscale.”
Captixbio Founder and CEO, Helen Wray, says the addition of Professor Stenzel to its Scientific & Clinical Advisory Panel will be a huge advantage for the company in achieving its goal of creating a cure for Type 1 Diabetes.
“We couldn’t be more excited to include someone of Martina’s calibre on our Scientific & Clinical Advisory Panel. Our SAP is critical to our development planning and to help lead the way in creating a unique cure for Type 1 Diabetes in Australia. Martina’s experience speaks for itself and we look forward to introducing her to the rest of the team!”
Alongside the panel, Professor Stenzel will continue her work as Professor & Co-Director of Centre for Advanced Macromolecular Design (CAMD) within the School of Chemical Engineering, a part of the faculty of science at UNSW, which is currently ranked 1st among Australian universities for research excellence and impact.
More on our Scientific & Clinical Advisory Panel here: https://captixbio.com.au/our-people/